9 Update information
November 2025: We have made minor editorial changes to the wording in section 1.1 to align with the NICE guideline on psoriasis: assessment and management. This does not affect the meaning or intent of the guidance.
March 2017: Under the original patient access scheme the company provided 2x45‑mg pre-filled syringes, for patients who needed the higher dose of 90‑mg, at the same total cost to the NHS as for a single 45‑mg pre-filled syringe. The patient access scheme has been withdrawn because the company now provides a 90‑mg vial at the same cost as the 45‑mg vial.
February 2014: Implementation section updated to clarify that ustekinumab is recommended as an option for treating moderate to severe psoriasis.
ISBN: 978-1-4731-2424-0